Patents by Inventor Gareth Neil Brace

Gareth Neil Brace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS
    Publication number: 20240294534
    Abstract: A series of substituted imidazo[1,2-b][1,2,4]triazine derivatives of formula (I), being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: June 30, 2022
    Publication date: September 5, 2024
    Inventors: Gareth Neil BRACE, Daniel Christopher BROOKINGS, Shuyu CHU, Rickki Lee CONNELLY, Anne Marie FOLEY, James Richard FROST, Ellen Olivia GALLIMORE, Paul GOLDSMITH, James Andrew JOHNSON, James Thomas REUBERSON, Robert STRAKER, Richard David TAYLOR, Luigi Piero STASI
  • IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS
    Publication number: 20240140951
    Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: December 6, 2021
    Publication date: May 2, 2024
    Inventors: Gareth Neil Brace, Shuyu Chu, Anne Marie Foley, James Andrew Johnson, Timothy John Norman, Joanna Rachel Quincey, James Thomas Reuberson, Robert Straker, Robert James Townsend
  • Fused imidazole derivatives as IL-17 modulators
    Patent number: 11472794
    Abstract: A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: October 18, 2022
    Assignee: UCB Biopharma SRL
    Inventors: Gareth Neil Brace, Rose Elizabeth Bardell-Cox, Gregory Foulkes, James Richard Frost, Helen Tracey Horsley, Elizabeth Pearl Jones, Fabien Claude Lecomte, James Thomas Reuberson, Monika-Sarah Elizabeth Dorothea Schulze, Richard David Taylor, Wei Tsung Yau, Zhaoning Zhu
  • Spirocyclic indane analogues as IL-17 modulators
    Patent number: 11458124
    Abstract: A series of substituted spirocyclic indane derivatives of Formula (I), and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: October 4, 2022
    Assignee: UCBBiopharma Srl
    Inventors: Gareth Neil Brace, Daniel Christopher Brookings, Gregory Foulkes, Fabien Claude Lecomte
  • Fused Imidazole Derivatives as IL-17 Modulators
    Publication number: 20220242855
    Abstract: A series of substituted fused bicyclic imidazole derivatives of formula (I), including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments including inflammatory and autoimmune disorders, wherein i. a. A represents C—R1 or N; B represents C—R2 or N; D represents C—R3 or N; E represents C—R4 or N; Z represents —CH(R5)N(H)CH2R6, —CH(R5)N(H)S(O)2R6, —C(?CR5aR5b)N(H)C(O)R6, —CH(R5)R7, —CH(R5)N(H)R7 or —CH(R5)C(O)N(H)R7; R0 represents hydrogen or C1-6 alkyl.
    Type: Application
    Filed: June 24, 2020
    Publication date: August 4, 2022
    Inventors: Shuyu Chu, Helen Tracey Horsley, James Thomas Reuberson, Richard David Taylor, Zhaoning Zhu, Rose Elizabeth Chappell, Gregory William Haslett, Adam Peter Smalley, Nathaniel Julius Thomas Monck, Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia
  • Imidazopyridine Derivatives as IL-17 Modulators
    Publication number: 20220227764
    Abstract: A series of substituted fused bicyclic imidazole derivatives, including imidazo[1,2-a]pyridine derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: June 24, 2020
    Publication date: July 21, 2022
    Inventors: Anne Marie Foley, Fabien Claude Lecomte, James Thomas Reuberson, Matthew Duncan Selby, Richard David Taylor, Paul Jonathan Hickford, Gareth Neil Brace
  • Spirocyclic Indane Analogues as IL-17 Modulators
    Publication number: 20210228547
    Abstract: A series of substituted spirocyclic indane derivatives of Formula (I), and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: July 8, 2019
    Publication date: July 29, 2021
    Inventors: Gareth Neil Brace, Daniel Christopher Brookings, Gregory Foulkes, Fabien Claude Lecomte
  • Spirocyclic indolines as IL-17 modulators
    Patent number: 11052076
    Abstract: A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: July 6, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Gareth Neil Brace, Rose Elizabeth Chappell, Hervé Jean Claude Deboves, Anne Marie Foley, Gregory Foulkes, Elizabeth Pearl Jones, Fabien Claude Lecomte, Joanna Rachel Quincey, Monika-Sarah Elisabeth Dorothea Schulze, Matthew Duncan Selby, Adam Peter Smalley, Richard David Taylor, Robert James Townsend, Zhaoning Zhu
  • Fused Imidazole Derivatives as IL-17 Modulators
    Publication number: 20210053952
    Abstract: A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: January 10, 2019
    Publication date: February 25, 2021
    Inventors: Gareth Neil Brace, Rose Elizabeth Chappell, Gregory Foulkes, James Richard Frost, Helen Tracey Horsley, Elizabeth Pearl Jones, Fabien Claude Lecomte, James Thomas Reuberson, Monika-Sarah Elizabeth Dorothea Schulze, Richard David Taylor, Wei Tsung Yau, Zhaoning Zhu
  • Spirocyclic Indolines as IL-17 Modulators
    Publication number: 20200138797
    Abstract: A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: June 12, 2018
    Publication date: May 7, 2020
    Inventors: Gareth Neil Brace, Rose Elizabeth Chappell, Hervé Jean Claude Deboves, Anne Marie Foley, Gregory Foulkes, Elizabeth Pearl Jones, Fabien Claude Lecomte, Joanna Rachel Quincey, Monika-Sarah Elisabeth Dorothea Schulze, Matthew Duncan Selby, Adam Peter Smalley, Richard David Taylor, Robert James Townsend, Zhaoning Zhu
  • Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity
    Patent number: 10287299
    Abstract: A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: May 14, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu
  • Fused tricyclic imidazole derivatives as modulators of TNF activity
    Patent number: 10087179
    Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: October 2, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Gareth Neil Brace, Julien Alistair Brown, Mark Daniel Calmiano, Prafulkumar Tulshibhai Chovatia, Michael Deligny, Ellen Olivia Gallimore, Jag Paul Heer, Victoria Elizabeth Jackson, Boris Kroeplien, Malcolm MacCoss, Joanna Rachel Quincey, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
  • Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity
    Publication number: 20180134728
    Abstract: A series of substituted 3,4-di-hydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: June 7, 2016
    Publication date: May 17, 2018
    Inventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu
  • Fused imidazole and pyrazole derivatives as modulators of TNF activity
    Patent number: 9868749
    Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 16, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Jonathan Mark Bentley, Gareth Neil Brace, Daniel Christopher Brookings, Prafulkumar Tulshibhai Chovatia, Hervé Jean Claude Deboves, Craig Johnstone, Elizabeth Pearl Jones, Boris Kroeplien, Fabien Claude Lecomte, James Madden, Craig Miller, John Robert Porter, Matthew Duncan Selby, Michael Alan Shaw, Darshan Gunvant Vaidya, Ian Andrew Yule
  • Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity
    Publication number: 20160376268
    Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: December 29, 2016
    Inventors: Rikki Peter ALEXANDER, Gareth Neil BRACE, Julien Alistair BROWN, Mark Daniel CALMIANO, Praful Tulshi CHOVATIA, Michael DELIGNY, Ellen Olivia GALLIMORE, Jag Paul HEER, Victoria Elizabeth JACKSON, Boris KROEPLIEN, Malcolm MAC COSS, Joanna Rachel QUINCEY, Yogesh Anil SABNIS, Dominique Louis Léon SWINNEN, Zhaoning ZHU, Uwe HEINELT, Volkmar WEHNER
  • Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity
    Publication number: 20160297837
    Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 13, 2016
    Inventors: Rikki Peter Alexander, Jonathan Mark Bentley, Gareth Neil Brace, Daniel Christopher Brookings, Praful Tulshi Chovatia, Hervé Jean Claude Deboves, Craig Johnstone, Elizabeth Pearl Jones, Boris Kroeplien, Fabien Claude Lecomte, James Madden, Craig Miller, John Robert Porter, Matthew Duncan Selby, Michael Alan Shaw, Darshan Gunvant Vaidya, Ian Andrew Yule